03 Profile
Vital Signsby Bridgehead
Hansard to 11 November 2026 · 31,429 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Sector leader · Rare diseases
Levi Garraway: no photograph is held, so the sector leader plate is shown instead.
Sector leader
Levi Garraway
Chief medical officer, Roche
1
0
0
2
0
0
June 2026July 2026Aug 2026Sept 2026Oct 2026Nov 2026to date
3
press citations on 1 topic since 30 Jun 2026 · last quoted 10 Sept 2026
02 Quoted on · 1 of 29 topics
Levi Garraway: key facts
- Kind of voice
- Sector leader
- Role
- Chief medical officer, Roche
- Quoted on
- Rare diseases
- Tracked press citations
- 3
- Most recently quoted
- 10 Sept 2026
- First quoted
- 30 Jun 2026
04 The signal · where Levi Garraway sits on rare diseases
Ranked 12= of 100 voices quoted in the press on rare diseases, level with 12 others on 3 citations.
Ranked on press citations on this topic only, not across all topics. Joint positions share a rank.
- 1Giles LomaxSector leaderChief Executive Officer, Spinal Muscular Atrophy UK (SMA UK)9
- 2Dr Harrison CarterAcademicDirector of Screening at NHS England8
- 3=
Prof Dame Sue HillRegulatorChief Scientific Officer for England and Senior Responsible Officer for Genomics, NHS England7 - 12=Dr Eamon McCarronClinicianConsultant and Clinical Lead in Adult Inherited Metabolic Disorders; Honorary Senior Lecturer, School of Medicine and Population Health, University of Sheffield, Sheffield Adult Metabolic Service, Sheffield Teaching Hospitals NHS Foundation Trust3
- 12=
Dr Karolina StepienClinicianConsultant in Adult Inherited Metabolic Diseases (Adult Metabolic Medicine), Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust3 - 12=Levi GarrawaySector leaderChief medical officer, Roche3
- 12=Iyamide ThomasSector leaderNHS Engagement Lead for Screening Programme3
- 12=
Vinay PrasadAcademicProfessor of Epidemiology and Biostatistics and Medicine; hematologist-oncologist, University of California, San Francisco (UCSF)3
Showing the leaders and the ranks around 12=, of 100 voices · See every voice on the topic →
05 On the record · press
What Levi Garraway has said
By outlet · linked articles
- pmlive.com2
- pharmaphorum.com1
Where Levi Garraway has been quoted
- 01Reviews underway of first drug for rare disease MOGADpharmaphorum.com · 10 Sept 2026
- 02Roche's Enspryng gets FDA Priority Review for autoimmune disease with no approved treatmentspmlive.com · 10 Sept 2026
- 03Roche's Enspryng given FDA Priority Review as thyroid eye disease treatmentpmlive.com · 30 Jun 2026
Verbatim
“Enspryng has the potential to transform care for people living with MOGAD, significantly reducing serious attacks and decreasing the reliance on high-dose steroids and immunosuppressants”
“MOGAD can be unpredictable and debilitating, with each relapse carrying the potential for lasting neurological damage, yet there are currently no approved treatments. Enspryng has the potential to transform care for people living with MOGAD, significantly reducing serious attacks and decreasing the reliance on high-dose steroids and immunosuppressants.”
“The FDA's decision to grant priority review to Enspryng is an important step toward expanding treatment options for people living with thyroid eye disease.”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
- Coventry tot's heartbreaking health battle after 'extremely rare' diagnosiscoventrytelegraph.net
- Takeda launches sleep disorder pill in the US after DEA clearance removes final hurdlereuters.com
- 'Immoral lottery' - Mum's plea after losing daughter to rare diseasethewestmorlandgazette.co.uk
Chief executives, directors and spokespeople of trade bodies, representative associations and charities speaking for the sector. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 12 Nov 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.